Nigerian-British businessman and social media influencer, Igho Ubiribo, had undergone five penile enlargement procedures at a clinic in Bangkok, Thailand, before his death in March, according to findings released by Thai health authorities.

The Department of Health Service Support (DHSS), under Thailand’s Ministry of Public Health, disclosed the development on Tuesday following an inspection of the clinic where Ubiribo received his final procedure.

Ubiribo, 43, who was also known by the names “Tiny,” “Denisi” and “Ego,” died after undergoing a penile filler procedure while on holiday in Thailand with his wife.

The latest disclosure has provided further details about his medical history at the clinic, including the number of procedures he had undergone and the circumstances surrounding the final treatment.

According to the DHSS, investigators were informed by the clinic’s management that Ubiribo had been a regular patient since 2024 and had undergone five injections intended to enlarge his penis.

The first four procedures were reportedly carried out between 2024 and 2025, while the fifth and final procedure took place on March 5, 2026, shortly before his death.

The final procedure involved the injection of 40 cubic centimetres (cc) of filler into his penis.

Thai authorities said the doctor who performed the procedure had recommended that the 40cc injection be divided into two separate sessions. However, Ubiribo reportedly preferred to have the entire amount administered during a single session.

The clinic told investigators that it provided Ubiribo with post-procedure instructions and subsequently followed up with him. According to the clinic, he did not report any complications or problems associated with the treatment before his condition deteriorated.

The authorities also said Ubiribo signed consent forms before each of the procedures he underwent at the facility.

The findings emerged after Thailand’s Minister of Public Health, Pattana Promphat, directed the DHSS and the country’s Food and Drug Administration to investigate the clinic following Ubiribo’s death.

Officials from the DHSS, working alongside the FDA, inspected the clinic on September 7 as part of efforts to establish what happened and determine whether the facility and medical professionals involved complied with applicable requirements.

The investigation began after emergency medical services received a request for an ambulance from a private hospital in Bangkok’s Sukhumvit area on March 5.

According to the account provided by Ubiribo’s wife, he had undergone a filler injection earlier that day before the couple went for a massage.

While at the hotel, Ubiribo reportedly complained of chest pain and subsequently lost consciousness. He was taken by ambulance to Sukhumvit Hospital, where doctors suspected that he could have suffered a blood clot.

Medical personnel reportedly prepared to conduct a high-speed CT scan with contrast dye, known as computed tomography angiography, to examine his blood vessels and establish the cause of his condition.

However, Ubiribo became unconscious and lost his pulse before the scan could be completed.

Doctors immediately began cardiopulmonary resuscitation (CPR) in an attempt to revive him. Despite prolonged resuscitation efforts, there was no response and he was pronounced dead in the early hours of March 6.

Thai authorities said the initial information surrounding the death prompted the subsequent investigation of the clinic located on Rama 1 Road in Bangkok’s Pathum Wan District.

The DHSS has stressed that its investigation is still ongoing and that the authorities have not, at this stage, announced a finding of professional malpractice against the clinic or the medical practitioners involved.

The Director-General of the DHSS, Phuwadej Surakhot, said officials would gather all relevant facts and evidence before referring the professional-practice aspects of the case to Thailand’s Medical Council.

“We will gather all facts and evidence to proceed according to our authority and submit the case to the Medical Council for a ruling on professional practice standards, in order to ensure fairness to all parties,” the authorities said.

The latest investigation follows earlier proceedings in the United Kingdom, where evidence presented to a coroner reportedly linked Ubiribo’s death to a pulmonary embolism following the cosmetic procedure.

Reports surrounding the UK inquest indicated that approximately 40 millilitres of a combination containing hyaluronic acid and lidocaine had been injected into his penis during the procedure.

Following the treatment, Ubiribo and his wife reportedly returned to their hotel and later went for a massage. It was during this period that he began experiencing chest pain and collapsed.

He was subsequently transported to hospital, where doctors suspected a pulmonary embolism and prepared to carry out diagnostic imaging.

However, his condition deteriorated before the planned scan could be performed. Medical personnel reportedly continued CPR for more than 100 minutes but were unable to revive him.

A subsequent postmortem examination reportedly found material in his lungs consistent with the hyaluronic acid used during the penile filler procedure.

The circumstances of his death have prompted renewed discussion among medical professionals about the risks associated with cosmetic procedures, particularly treatments that are sometimes perceived by members of the public as less risky because they do not involve conventional surgery.

Following Ubiribo’s death, aesthetic medicine and dermatology physician Dr Mobola Savage warned that penile fillers should not be regarded as risk-free procedures.

“Non-surgical does not mean risk-free. Penile filler is still an invasive medical procedure involving highly vascular anatomy,” Savage said in a statement shared on X.

She explained that the treatment Ubiribo underwent was not conventional penile enlargement surgery but a form of non-surgical penile augmentation, generally intended to increase penile girth.

The distinction is significant because non-surgical procedures can still involve injections, tissue manipulation and other medical interventions that carry potential complications.

The Thai authorities are now examining the clinic’s operations, the treatment administered to Ubiribo and the professional conduct of the medical personnel involved.

The investigation is expected to determine whether the procedure was performed in accordance with Thailand’s medical and professional standards, whether the clinic complied with applicable regulations and whether any aspect of the treatment contributed to the circumstances surrounding Ubiribo’s death.

Authorities have yet to make a final determination on professional liability.

The case has nevertheless highlighted the importance of proper medical assessment, informed consent and professional oversight in cosmetic procedures.

It has also raised questions about the growing popularity of non-surgical cosmetic treatments and the need for patients to understand that procedures involving injectable fillers can carry serious medical risks.

For now, Thai health authorities say they will continue gathering evidence before submitting the professional-practice aspects of the case to the Medical Council.

Until that process is completed, no conclusion of malpractice has been formally announced against the clinic or its medical personnel. The investigation remains ongoing as authorities seek to establish the full circumstances surrounding the death of the Nigerian-British businessman.